ADNOC Gas Targets Up to $4B Profit in 2026 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak 
Yes, government influences wages – but not just in the way you might think 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
S&P 500, Nasdaq Slip as Oil Jumps on Iran Tensions 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise 
European Stocks Flat as Oil Prices Rise, US CPI in Focus 
Why a ‘rip-off’ degree might be worth the money after all – research study 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
Can your cat recognise you by scent? New study shows it’s likely 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Gold Price Hits Two-Month High as Investors Await US Inflation Data 
Bubs Australia will manufacture and distribute Bubs’ Chinese-label goat milk infant formula in China according to new Chinese standards. under an agreement with Heilongjiang Ubeite Dairy Group (HUG).
The new standards will come into effect in February 2023 .
The “ultra-premium” infant formula has been specially developed for Chinese infants using easily-digestible A2 goat-milk protein, sn2 palmitate (OPO), lactoferrin prebiotics, and nucleotides.
HUG has started submission with the State Administration for Market Regulation (SAMR) to renew its registration in line with China’s new GB standards for exclusive use under the Bubs brand.
According to Kristy Carr, Bubs founder and CEO, they have built strong brand trust and loyalty with Chinese families through marketing and selling Bubs English label infant formula products via the crossborder eCommerce channel, which accounts for around 20 percent of total Chinese infant formula sales.
If approved by SAMR, the formula will give Bubs access to the remaining 80 percent of China’s $25.9 billion infant formula market.
Bubs will also enter into a joint venture agreement, where it will hold a 75 percent interest, with Zhitong Health Technology to distribute its Chinese label goat infant formula products.
Bubs Australia expects to launch its product in the second half of FY23, subject to receiving SAMR approval.
